Pieris Pharmaceuticals, Inc. - PIRS Enterprise Value-to-Revenue Multiple

Pieris Pharmaceuticals Inc (PIRS) - corporate logo

Pieris Pharmaceuticals management is currently focused on strict cost-cutting and seeking allies for survival. This EV/Sales chart demonstrates the asset's current resilience, where the current mark equals 0.00, helping to avoid buying at the peak. A unique patent portfolio serves as a business defense, while growth potential is based on innovative anticalin proteins that are attracting the attention of pharmaceutical behemoths.

Pieris Pharmaceuticals - PIRS EV/Sales Multiple (period 11/23/2025 - 11/20/2026)

Financial and market metric breakdowns for Pieris (PIRS)

Initial company analysis:Pieris Pharmaceuticals
Original product of Pieris Pharmaceuticals Inc

An investment audit of Pieris Pharmaceuticals (PIRS) requires an EV/Sales analysis, which determines the business value inclusive of net debt relative to sales volume to eliminate market distortions. This calculation enables an assessment of resource capitalization efficiency, including costs for complex protein cold-chain logistics, reflecting the real market value of assets through the EV-to-revenue ratio.

Competitor analysis for Pieris Pharmaceuticals

HLN: Enterprise Value-to-Revenue Ratio|Kenvue Corp (KVUE) - Enterprise Value-to-Revenue Ratio|Verona Pharma PLC - Business Value to Revenue|Enterprise Value-to-Revenue Ratio Jyong Biotech Ltd|EV/Sales Multiple Ligand Corp|EV/Sales Multiple AMRX|Total Company Value-to-Revenue Ratio Perrigo Company plc|EV/Sales Multiple ALVO (Alvotech Biopharmaceuticals)|LQDA: Company Value to Revenue Ratio|Galapagos N.V. - EV/Sales Multiple|ANIP - EV/Sales Multiple|MNKD: EV/Sales Multiple|amphastar.com (AMPH) - EV/Sales Multiple|PCRX (Pacira Pharmaceuticals) - EV/Sales Multiple|Company Value to Revenue ARS Pharmaceuticals, Inc. (SPRY)|EV/Sales Multiple TBPH|AQST (Aquestive Therapeutics) - Business Value to Revenue|scPharmaceuticals, Inc. - Company Value to Revenue|Business Value to Revenue TECX|tonixpharma.com - EV/Sales Multiple|Business Value to Revenue SXTC (sxtchina.com)|Eupraxia Pharma (EPRX) - Enterprise Value-to-Revenue Ratio|Company Value to Revenue BioHarvest|Company Value to Revenue EXOZ|Company Value to Revenue Oramed Pharmaceuticals (ORMP)|Company Value to Revenue ENTX (Entera Bio Corp)|MindWalk Holdings Inc. - Company Value to Revenue Ratio|EV/Sales Multiple ABVC (ABVC BioPharma Inc)|CPIX - Company Value to Revenue|Quantum BioPharma Corp - EV/Sales Multiple|FGEN (fibrogen.com) - Company Value to Revenue Ratio|TELO (Telomir Pharmaceuticals) - Company Value to Revenue|Rani Therapeutics Holdings - Business Value to Revenue|Company Value to Revenue SNYR|Enterprise Value-to-Revenue Multiple rallybio.com RLYB|EV/Sales Multiple LEXX|PULM (Pulmatrix, Inc.) - Business Value to Revenue|Pheton Holdings - Company Value to Revenue|EV/Sales Multiple Aptorum Group Limited APM|LYRA: Company Value to Revenue|IBO: Enterprise Value-to-Revenue Ratio|TNFA: EV/Sales Multiple|YCBD: Enterprise Value-to-Revenue Coefficient|Enterprise Value-to-Revenue Ratio PainReform Ltd|CYTO (altamiratherapeutics.com) - Enterprise Value-to-Revenue Coefficient|EV/Sales Multiple LIPO|OPTN - Enterprise Value-to-Revenue Multiple|Enterprise Value-to-Revenue Ratio Procaps Group S.A. PROC|Total Company Value-to-Revenue Ratio petrospharma.com (PTPI)|QLI - Enterprise Value-to-Revenue Ratio|Business Value to Revenue SLRN (ACELYRIN)|TFF Pharmaceuticals, Inc (TFFP) - Enterprise Value-to-Revenue Ratio